PMID- 23464419
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 12
DP  - 2012
TI  - Expression and clinical significance of mTOR in surgically resected non-small 
      cell lung cancer tissues: a case control study.
PG  - 6139-44
AB  - AIMS: Mammalian target of rapamycin (mTOR) is master regulator of the 
      PI3K/Akt/mTOR pathway and plays an important role in NSCLCs. Here we 
      characterized mRNA and protein expression levels of mTOR and its functional 
      associated molecules including PTEN, IGF-1R and 4EBP1 in surgically resected 
      NSCLCs. METHODS: Fifty-four patients with NSCLCs who underwent pulmonary 
      resection were included in current study. mRNA levels of mTOR, PTEN, IGF-1R, and 
      4EBP1 were evaluated by RT-PCR and protein expression of mTOR, PTEN, and IGF-1R 
      by immunohistochemistry (IHC). Association of expression of the relevant 
      molecules with clinical characteristics, as well as correlations between mTOR and 
      PTEN, 4EBP1 and IGF-1R were also assessed. RESULTS: The results of RT-PCR showed 
      that in NSCLCs, the expression level of mTOR increased, while PTEN, 4EBP1 and 
      IGF-1R decreased. Statistical analysis indicated high IGF-1R expression was 
      correlated with advanced clinical stage (stage III) and PTEN expression was 
      reversely associated with tumor size (P=0.16). The results of IHC showed mTOR 
      positive staining in 51.8% of cases, while IGF-1R positive staining was found in 
      83.3% and loss of PTEN in 46.3%. Protein expression of mTOR was correlated with 
      its regulators, PTEN and IGF-1R, to some extent. CONCLUSIONS: Abnormal activation 
      of mTOR signaling, high expression of IGF-1R, and loss of PTEN were observed in 
      resected NSCLC specimens. The poor expression agreement of mTOR with its 
      regulators, PTEN, and IGF-1R, implied that combination strategy of mTOR 
      inhibitors with other targets hold significant potential for NSCLC treatment.
FAU - Liu, Zhe
AU  - Liu Z
AD  - Department of Oncology, Beijing Chest Hospital, Capital Medical University of 
      China, Beijing, China. liuzhe1968@yahoo.com.cn
FAU - Wang, Liang
AU  - Wang L
FAU - Zhang, Li-Na
AU  - Zhang LN
FAU - Wang, Yue
AU  - Wang Y
FAU - Yue, Wen-Tao
AU  - Yue WT
FAU - Li, Qi
AU  - Li Q
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Animals
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Case-Control Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms
MH  - *Phosphatidylinositol 3-Kinases/metabolism
MH  - Receptor, IGF Type 1/metabolism
MH  - Signal Transduction
EDAT- 2012/01/01 00:00
MHDA- 2016/04/24 06:00
CRDT- 2013/03/08 06:00
PHST- 2013/03/08 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
AID - 10.7314/apjcp.2012.13.12.6139 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(12):6139-44. doi: 10.7314/apjcp.2012.13.12.6139.